NuCana plc (NASDAQ:NCNA) Short Interest Update

NuCana plc (NASDAQ:NCNA) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 8,800 shares, a decline of 49.1% from the February 28th total of 17,300 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average trading volume of 113,200 shares, the short-interest ratio is presently 0.1 days.

Institutional Investors Weigh In On NuCana

A number of hedge funds have recently modified their holdings of NCNA. Virtu Financial LLC bought a new position in NuCana in the 4th quarter worth $48,000. Two Sigma Securities LLC bought a new position in shares of NuCana in the fourth quarter worth about $25,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of NuCana during the 4th quarter valued at about $54,000. Finally, Citadel Advisors LLC bought a new position in shares of NuCana during the 4th quarter valued at approximately $30,000. Institutional investors own 44.00% of the company’s stock.

NuCana Trading Up 6.2 %

NCNA stock traded up $0.07 during trading on Friday, reaching $1.14. The stock had a trading volume of 471,139 shares, compared to its average volume of 425,272. The firm has a market cap of $3.00 million, a PE ratio of -0.11 and a beta of 0.89. The stock’s 50 day moving average is $0.95 and its two-hundred day moving average is $1.48. NuCana has a 52 week low of $0.69 and a 52 week high of $10.79.

NuCana (NASDAQ:NCNA) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($2.43) by $2.11. On average, research analysts anticipate that NuCana will post -13.42 EPS for the current year.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.